Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 233

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Gene therapy clinical trials, where do we go? An overview

Open access
Arabi, Fatemeh, Mansouri, Vahid, Ahmadbeigi, Naser · 2022 · Biomedicine & Pharmacotherapy

Abstract

There have been many ups and downs since the introduction of gene therapy as a therapeutic modality for diseases. However, the journey of gene therapy has reached a fundamental milestone, as evidenced by the increasing number of gene therapy products on the market. Looking at the currently approved and under-approval products, as well as the numerous clinical trials in this field, gene therapy has a promising future. Trend of changes in gene therapy strategies, vectors, and targets could be insightful for pharmaceutical companies, policymakers, and researchers. In this paper, following a brief history of gene therapy, we reviewed current gene therapy products as well as gene therapies that may be approved in the near future. We also looked at ten-year changes in gene therapy clinical trials strategies, such as the use of vectors, target cells, transferred genes, and ex-vivo/in-vivo methods, as well as the major fields that gene therapy has entered. Although gene therapy was initially used to treat genetic diseases, cancer now has the greatest number of gene therapy clinical trials. Changes in gene therapy strategies, particularly in pioneering countries in this field, may point to the direction of future clinical products.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.biopha.2022.113324

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Research works printed but not linked: 79

  1. Anderson, 1990, September 14, 1990: the beginning, Hum. Gene Ther., 1, 371, 10.1089/hum.1990.1.4-371 · doi:10.1089/hum.1990.1.4-371
  2. Portin, 2017, The evolving definition of the term “gene”, Genetics, 205, 1353, 10.1534/genetics.116.196956 · DOI
  3. Wolff, 1994, An early history of gene transfer and therapy, Hum. Gene Ther., 5, 469, 10.1089/hum.1994.5.4-469 · DOI
  4. Arber, 1969, DNA modification and restriction, Annu. Rev. Biochem., 38, 467, 10.1146/annurev.bi.38.070169.002343 · DOI · Paper page
  5. Lehman, 1974, DNA ligase: structure, mechanism, and function, Science, 186, 790, 10.1126/science.186.4166.790 · DOI · Paper page
  6. Friedmann, 1992, A brief history of gene therapy, Nat. Genet., 2, 93, 10.1038/ng1092-93 · DOI · Paper page
  7. Mulligan, 1993, The basic science of gene therapy, Science, 260, 926, 10.1126/science.8493530 · DOI · Paper page
  8. Williams, 1984, Introduction of new genetic material into pluripotent haematopoietic stem cells of the mouse, Nature, 310, 476, 10.1038/310476a0 · DOI · Paper page
  9. Merrouche, 1995, Clinical application of retroviral gene transfer in oncology: results of a French study with tumor-infiltrating lymphocytes transduced with the gene of resistance to neomycin, J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol., 13, 410, 10.1200/JCO.1995.13.2.410 · DOI
  10. Blaese, 1995, T lymphocyte-directed gene therapy for ADA- SCID: initial trial results after 4 years, Science, 270, 475, 10.1126/science.270.5235.475 · DOI · Paper page
  11. King, 2017, New treatments for serious conditions: ethical implications, Gene Ther., 24, 534, 10.1038/gt.2017.32 · doi:10.1038/gt.2017.32
  12. Cavazzana-Calvo, 2000, Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease, Science, 288, 669, 10.1126/science.288.5466.669 · DOI · Paper page
  13. Howe, 2008, Insertional mutagenesis combined with acquired somatic mutations causes leukemogenesis following gene therapy of SCID-X1 patients, J. Clin. Investig., 118, 3143, 10.1172/JCI35798 · DOI · Paper page
  14. Zhang, 2018, The first approved gene therapy product for cancer Ad-p53 (gendicine): 12 years in the clinic, Hum. Gene Ther., 29, 160, 10.1089/hum.2017.218 · DOI · Paper page
  15. Liang, 2018, Oncorine, the world first oncolytic virus medicine and its update in China, Curr. Cancer Drug Targets, 18, 171, 10.2174/1568009618666171129221503 · DOI · Paper page
  16. Gruber, 2012, Europe gives gene therapy the green light, Lancet, 380, 10.1016/S0140-6736(12)61992-8 · DOI
  17. Padhy, 2020, Voretigene neparvovec and gene therapy for leber’s congenital amaurosis: review of evidence to date, Appl. Clin. Genet., 13, 179, 10.2147/TACG.S230720 · DOI
  18. Mahajan, 2019, Onasemnogene abeparvovec for spinal muscular atrophy: the costlier drug ever, Int. J. Appl. Basic Med. Res., 9, 127, 10.4103/ijabmr.IJABMR_190_19 · DOI
  19. Shahryari, 2019, Development and clinical translation of approved gene therapy products for genetic disorders, Front. Genet., 10, 868, 10.3389/fgene.2019.00868 · DOI · Paper page
  20. Ma, 2020, The approved gene therapy drugs worldwide: from 1998 to 2019, Biotechnol. Adv., 40, 10.1016/j.biotechadv.2019.107502 · DOI · Paper page
  21. Anguela, 2019, Entering the modern era of gene therapy, Annu. Rev. Med., 70, 273, 10.1146/annurev-med-012017-043332 · DOI · Paper page
  22. Batty, 2019, Advances and challenges for hemophilia gene therapy, Hum. Mol. Genet., 28, R95, 10.1093/hmg/ddz157 · DOI
  23. Zarogoulidis, 2013, Suicide gene therapy for cancer - current strategies, J. Genet. Syndr. Gene Ther., 4, 16849
  24. Nakagami, 2021, Development of COVID-19 vaccines utilizing gene therapy technology, Int. Immunol., 33, 521, 10.1093/intimm/dxab013 · DOI
  25. Chow, 2018, Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma, Blood, 132, 777, 10.1182/blood-2018-04-839217 · DOI
  26. Mitrpant, 2013, Improved antisense oligonucleotide design to suppress aberrant SMN2 gene transcript processing: towards a treatment for spinal muscular atrophy, PLoS One, 8, 10.1371/journal.pone.0062114 · DOI
  27. Uddin, 2020, CRISPR gene therapy: applications, limitations, and implications for the future, Front. Oncol., 10, 1387, 10.3389/fonc.2020.01387 · DOI · Paper page
  28. Maurer, 2018, Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy, N. Engl. J. Med., 379, 1007, 10.1056/NEJMoa1805689 · DOI · Paper page
  29. Bulaklak, 2020, The once and future gene therapy, Nat. Commun., 11, 5820, 10.1038/s41467-020-19505-2 · DOI · Paper page
  30. Junghans, 2017, The challenges of solid tumor for designer CAR-T therapies: a 25-year perspective, Cancer Gene Ther., 24, 89, 10.1038/cgt.2016.82 · DOI
  31. Xu, 2019, Generation of CAR-T cells for cancer immunotherapy, Methods Mol. Biol., 1884, 349, 10.1007/978-1-4939-8885-3_24 · DOI
  32. Mansouri, 2021, Recent advances in regenerative medicine strategies for cancer treatment, Biomed. Pharmacother., 141, 10.1016/j.biopha.2021.111875 · DOI
  33. Jayaraman, 2020, CAR-T design: elements and their synergistic function, EBioMedicine, 58, 10.1016/j.ebiom.2020.102931 · DOI · Paper page
  34. Tokarew, 2019, Teaching an old dog new tricks: next-generation CAR T cells, Br. J. Cancer, 120, 26, 10.1038/s41416-018-0325-1 · DOI · Paper page
  35. Zhao, 2021, Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons, Front. Immunol., 12
  36. Fu, 2020, DC-based vaccines for cancer immunotherapy, Vaccines, 706, 10.3390/vaccines8040706 · DOI
  37. Bouard, 2009, Viral vectors: from virology to transgene expression, Br. J. Pharmacol., 157, 153, 10.1038/bjp.2008.349 · DOI · Paper page
  38. Goswami, 2019, Gene therapy leaves a vicious cycle, Front. Oncol., 9, 297, 10.3389/fonc.2019.00297 · DOI · Paper page
  39. Ghosh, 2020, Viral vector systems for gene therapy: a comprehensive literature review of progress and biosafety challenges, Appl. Biosaf., 25, 7, 10.1177/1535676019899502 · DOI · Paper page
  40. Ura, 2014, Developments in viral vector-based vaccines, Vaccines, 624, 10.3390/vaccines2030624 · DOI · Paper page
  41. Bulcha, 2021, Viral vector platforms within the gene therapy landscape, Signal Transduct. Target. Ther., 6, 53, 10.1038/s41392-021-00487-6 · DOI · Paper page
  42. Labbe, 2021, Lentiviral vectors for T cell engineering: clinical applications, bioprocessing and future perspectives, Viruses, 13, 1528, 10.3390/v13081528 · DOI
  43. Gao, 2020, Expanding the spectrum of adenoviral vectors for cancer therapy, Cancers, 1139, 10.3390/cancers12051139 · DOI
  44. Gao, 2019, State-of-the-art human adenovirus vectorology for therapeutic approaches, FEBS Lett., 593, 3609, 10.1002/1873-3468.13691 · DOI
  45. Sainz-Ramos, 2021, How far are non-viral vectors to come of age and reach clinical translation in gene therapy?, Int. J. Mol. Sci., 22, 7545, 10.3390/ijms22147545 · DOI
  46. Chira, 2015, Progresses towards safe and efficient gene therapy vectors, Oncotarget, 6, 30675, 10.18632/oncotarget.5169 · DOI · Paper page
  47. Jafarlou, 2016, An overview of the history, applications, advantages, disadvantages and prospects of gene therapy, J. Biol. Regul. Homeost. Agents, 30, 315
  48. Razi Soofiyani, 2013, Gene therapy, early promises, subsequent problems, and recent breakthroughs, Adv. Pharm. Bull., 3, 249
  49. Selkirk, 2004, Gene therapy in clinical medicine, Postgrad. Med. J., 80, 560, 10.1136/pgmj.2003.017764 · DOI
  50. Stein, 2017, FDA-approved oligonucleotide therapies in 2017, Mol. Ther., 25, 1069, 10.1016/j.ymthe.2017.03.023 · DOI · Paper page
  51. Guo, 2018, Development of gene therapeutics for head and neck cancer in China: from bench to bedside, Hum. Gene Ther., 29, 180, 10.1089/hum.2017.230 · DOI
  52. Pearson, 2004
  53. Gordon, 2009, The ‘timely’development of Rexin-G: first targeted injectable gene vector, Int. J. Oncol., 35, 229
  54. Ylä-Herttuala, 2012, Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union, Mol. Ther., 20, 1831, 10.1038/mt.2012.194 · DOI · Paper page
  55. Poh, 2016, First oncolytic viral therapy for melanoma, Cancer Discov., 6, 6, 10.1158/2159-8290.CD-NB2015-158 · DOI
  56. Ott, 2016, Talimogene laherparepvec for the treatment of advanced melanoma, Clin. Cancer Res., 22, 3127, 10.1158/1078-0432.CCR-15-2709 · DOI
  57. Farkas, 2017, Advanced therapy medicinal products for rare diseases: state of play of incentives supporting development in Europe, Front. Med, 4, 53, 10.3389/fmed.2017.00053 · DOI
  58. Hoggatt, 2016, Gene therapy for “Bubble Boy” disease, Cell, 166, 263, 10.1016/j.cell.2016.06.049 · DOI
  59. Schimmer, 2016, Investor outlook: rising from the ashes; GSK’s European Approval of Strimvelis for ADA-SCID, Hum. Gene Ther. Clin. Dev., 27, 57, 10.1089/humc.2016.29010.ind · DOI
  60. Stirnadel-Farrant, 2018, Gene therapy in rare diseases: the benefits and challenges of developing a patient-centric registry for Strimvelis in ADA-SCID, Orphanet J. Rare Dis., 13, 49, 10.1186/s13023-018-0791-9 · DOI
  61. Aartsma-Rus, 2019, A sequel to the eteplirsen saga: eteplirsen is approved in the United States but was not approved in Europe, Nucleic Acid. Ther., 29, 13, 10.1089/nat.2018.0756 · DOI
  62. Korinthenberg, 2019, A new era in the management of Duchenne muscular dystrophy, Dev. Med. Child Neurol., 61, 292, 10.1111/dmcn.14129 · DOI
  63. Ottesen, 2017, ISS-N1 makes the first FDA-approved drug for spinal muscular atrophy, Transl. Neurosci., 8, 1, 10.1515/tnsci-2017-0001 · DOI · Paper page
  64. Russell, 2017, Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial, Lancet, 390, 849, 10.1016/S0140-6736(17)31868-8 · DOI · Paper page
  65. Neelapu, 2017, Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma, N. Engl. J. Med., 377, 2531, 10.1056/NEJMoa1707447 · DOI · Paper page
  66. Evans, 2018, Arthritis gene therapy is becoming a reality, Nat. Rev. Rheumatol., 14, 381, 10.1038/s41584-018-0009-5 · DOI
  67. Evans, 2018, Arthritis gene therapy approved in Korea, J. Am. Acad. Orthop. Surg., 26, e36, 10.5435/JAAOS-D-17-00695 · DOI
  68. Gales, 2019, Tegsedi (inotersen): an antisense oligonucleotide approved for the treatment of adult patients with hereditary transthyretin amyloidosis, Pharmaceuticals, 78, 10.3390/ph12020078 · DOI
  69. Suda, 2014, Beperminogene perplasmid for the treatment of critical limb ischemia, Expert Rev. Cardiovasc. Ther., 12, 1145, 10.1586/14779072.2014.955850 · DOI
  70. Hoy, 2019, Onasemnogene abeparvovec: first global approval, Drugs, 79, 1255, 10.1007/s40265-019-01162-5 · DOI · Paper page
  71. Y.A. Heo, Golodirsen: first approval, Drugs, 80, 2020, pp. 329–333. 〈10.1007/s40265-020-01267-2〉. · DOI · Paper page
  72. J. Paik, S. Duggan, Volanesorsen: first global approval, Drugs, 79, pp. 1349–1354. 〈10.1007/s40265-019-01168-z〉. · DOI · Paper page
  73. Y.N. Lamb, BNT162b2 mRNA COVID-19 vaccine: first approval, Drugs, 81, 2021, pp. 495–501. 〈10.1007/s40265-021-01480-7〉. · DOI · Paper page
  74. L.J. Scott, Givosiran: first approval, Drugs, 80, 2020, pp. 335–339. 〈10.1007/s40265-020-01269-0〉. · DOI · Paper page
  75. L.J. Scott, S.J. Keam, Lumasiran: first approval, Drugs, 81, 2021, pp. 277–282. 〈10.1007/s40265-020-01463-0〉. · DOI · Paper page
  76. Roshmi, 2021, Pharmacological profile of viltolarsen for the treatment of duchenne muscular dystrophy: a Japanese experience, Clin. Pharmacol., 13, 235
  77. Migliorati, 2022, siRNA drug Leqvio (inclisiran) to lower cholesterol, Trends Pharmacol. Sci., 43, 455, 10.1016/j.tips.2022.02.003 · DOI
  78. Ortiz-Maldonado, 2022, Results of ARI-0001 CART19 cells in patients with chronic lymphocytic leukemia and Richter’s transformation, Front. Oncol., 12, 10.3389/fonc.2022.828471 · DOI
  79. Press Release Daiichi Sankyo Launches DELYTACT ® Oncolytic Virus G47∆ in Japan. Available from: 〈www.daiichisankyo.com〉.

Cited by

See all 233

Metadata

Authors
Arabi, F., Mansouri, V., & Ahmadbeigi, N.
Venue
Biomedicine & Pharmacotherapy
Publisher
Elsevier BV
Published
2022-09
Volume
153
Pages
113324
ISSN
0753-3322 (ISSN-L)
OpenAlex
W4283778388
Cited by
233
References
15
FWCI
28.00
Type
journal article
Language
en
Open access
gold
Licence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Gene therapy clinical trials, where do we go? An overview. https://app.cochat.ai/papers/10.1016/j.biopha.2022.113324
The paper
Arabi, F., Mansouri, V., & Ahmadbeigi, N. (2022). Gene therapy clinical trials, where do we go? An overview. Biomedicine & Pharmacotherapy. https://doi.org/10.1016/j.biopha.2022.113324

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.